NRx Pharmaceuticals prices $2.0M public offering of common stock at $3.30 per share

NRX Pharmaceuticals, Inc.

Underwritten public offering of 607,000 shares at $3.30/share; gross proceeds ~$2.0M before expenses.
Underwriters granted 45-day option for up to 91,050 additional shares at same price to cover over-allotments.
Company will issue to representative EF Hutton a warrant to purchase up to 30,350 shares (5% of shares sold) at $3.63/share.
Net proceeds to be used for working capital, general corporate purposes, and potential repayment of Streeterville Capital note.
Offering closed on April 19, 2024; shares sold under existing effective shelf registration statement.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NRX Pharmaceuticals, Inc. entered into Underwriting Agreement with EF Hutton LLC valued at approximately $2.0 million (effective 2024-04-18).

Action: entry
Agreement: underwriting
Counterparty: EF Hutton LLC
Value: approximately $2.0 million
Effective: 2024-04-18

Exact text from the filing

On April 18, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with EF Hutton LLC (the “ Representative ”), as the representative of the several underwriters named therein (the “ Underwriters ”), relating to an underwritten public offering (the “ Offering ”) of 607,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (“ Common Stock ”).

View on SEC.gov

284 material agreements filed in the last 30 days. Browse all material agreements →

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-049529

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.